NIP
CLDX icon

Nicholas Investment Partners’s Celldex Therapeutics CLDX Stock Holding History

Nicholas Investment Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,793
Closed -$5.74M – 298
2013
Q3 		$5.74M Buy
+10,793
New +$3.7M 0.48% 37

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Nicholas Investment Partners's CLDX Position: Q4 2013 in Review

Nicholas Investment Partners sold out of Celldex Therapeutics (CLDX) in Q4 2013, closing a stake of 10,793 shares — an estimated $5.74M sold.

Nicholas Investment Partners first reported a position in CLDX in Q3 2013 and held it in 1 quarter. The position peaked at $5.74M in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

  • Nicholas Investment Partners reported no remaining Celldex Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Nicholas Investment Partners sold 10,793 Celldex Therapeutics shares in Q4 2013, an estimated $5.74M.
  • Nicholas Investment Partners first reported a position in Celldex Therapeutics in Q3 2013 and held it in 1 quarter.
  • Nicholas Investment Partners's Celldex Therapeutics position peaked at $5.74M in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on Nicholas Investment Partners's 13F filing for Q4 2013, filed 13 Feb 2014.